Fig. 4. MET depletion enhances liver cancer vaccination in an AKT-independent manner.

a Strategy for investigating the dependency of AKT in MET-controlled liver cancer vaccination. b–e AKT activation was not able to repress MET deficiency-enhanced liver cancer immunogenicity. Wild-type (WT) and MET-deficient (MET-KO) H22 cells (b, c) and Hepa1-6 cells (d, e) were individually transfected with the Akt T308D/S473D (AKT-DD) mutant, subsequently treated with cisplatin (CDDP), oxaliplatin (OXP), or vehicle control (Ctrl), respectively, and then subcutaneously (s.c.) injected into the left flank of C57BL/6 mice. One week later, all the mice were rechallenged with homologous untreated WT cells in the right flank. The tumor incidence is reported as Kaplan–Meier curves. Significance was determined by the means calculated with a likelihood ratio test. *p-Value < 0.05, **p-value < 0.01, ***p-value < 0.001, ns (nonsignificant), compared to the indicated groups; n = 10 per group.